ABSTRACT
Objective:To investigate the effect of dexmedetomidine combined with butorphanol on perioperative analgesia in patients subjected to cardiac surgery.Methods:Sixty-three patients who underwent elective cardiac surgery in Weihai Central Hospital from June 2019 to August 2020 were included in this study. They were divided into propofol + sufentanil group ( n = 21), dexmedetomidine + sufentanil group ( n = 23) and dexmedetomidine + butorphanol group ( n = 19) according to different analgesic methods. Postoperative analgesic satisfaction, Visual Analogue Scale score, hemodynamic changes (heart rate, respiratory rate, systolic blood pressure, diastolic blood pressure) and adverse reactions were compared among the three groups. Results:The satisfaction rate of postoperative analgesia in the dexmedetomidine + butorphanol group was 94.7% (18/19), which was significantly higher than 61.9% (13/21) in the propofol + sufentanil group and 60.8% (14/23) in the dexmedetomidine + sufentanil group ( χ2 = 6.16, 6.57, both P < 0.05). At 4, 12, 24 and 48 hours after tracheal extubation, Visual Analogue Scale score in the dexmedetomidine + butorphanol group were significantly lower than that in the propofol + sufentanil group and dexmedetomidine + sufentanil group (both P < 0.05). At the time of tracheal extubation and at 5 minutes after tracheal extubation, heart rate, respiratory rate, systolic blood pressure and diastolic blood pressure in the dexmedetomidine+butorphanol group were significantly lower than those in the propofol + sufentanil group and dexmedetomidine + sufentanil group (both P < 0.05). The incidence of adverse reactions in the dexmedetomidine + butorphanol group was 10.5% (2/19), which was significantly lower than 23.8% (5/21) in the propofol + sufentanil group and 30.43% (7/23) in the dexmedetomidine + sufentanil group [30.4% (7/23), χ2=21.94, P < 0.001]. Conclusion:Dexmedetomidine combined with butorphanol in cardiac surgery can not only stabilize postoperative blood pressure and heart rate, but also lower the degree of pain and is highly safe.
ABSTRACT
Objective:To investigate the effects of circ_0000285/miR-127/VAMP2 axis on proliferation and invasion of ovarian cancer (OC) cells.Methods:Real-time quantitative polymerase chain reaction (qRT-PCR) was used to detect the expression of circ_0000285, miR-127 and VAMP2 in tissue with OC and normal tissue respectively, and the correlation circ_0000285/miR-127/VAMP2 was analyzed by correlation analysis. Dual luciferase reporter assay was used to verify the targeting relationship between miR-127 and circ_0000285/VAMP2. Cell proliferation and invasion were subsequently detected by MTT and Transwell assay.Results:Compared with the paracancerous tissue, the expression of miR-127 was significantly decreased, while the expression of circ_0000285 and VAMP2 was increased in OC tissue. miR-127 was negatively correlated with circ_0000285 and VAMP2 ( r=-0.534 8, P<0.000 1; r=-0.376 6, P<0.000 1) . Compared with proliferative activity at 24 h, 48 h, 72 h (0.47±0.03) (0.79±0.05) (1.16±0.09) and invasion (100.00±12.33) in si-NC group, knocking down of circ_0000285 inhibited the proliferation (0.28±0.02) (0.51±0.04) (0.78±0.06) and invasion (49.22±5.08) of OC cells (all P<0.05) . Overexpression of miR-127 could also restrain proliferation, invasion of OC cells, but this effect can be partly saved by circ_0000285. The regulation circ_0000285 on OC may be realized through miR-127/VAMP2. Conclusions:circ_0000285 participates in the progression of ovarian cancer via regulating miR-127/VAMP2 axis. Down-regulating the expression of circ_0000285 inhibits the proliferation and invasion of ovarian cancer cells, circ_0000285 is expected to play a role in the targeted therapies of OC.
ABSTRACT
Objective:To study the correlation between insulin-like growth factor-1 (IGF-1) and its receptor IGF-1R expression in ovarian cancer and clinicopathological features, surgical prognosis.Methods:The positive expression rates of IGF-1 and IGF-1R in ovarian cancer, borderline ovarian tumors and benign ovarian tumors were detected by immunohistochemistry. The correlation of IGF-1 and IGF-1R with clinicopathological features, surgical prognosis was analyzed.Results:The positive expression rate of IGF-1 and IGF-1R in ovarian cancer was 65.63%, 70.31%, significantly higher than 22.22%, 16.67% in borderline ovarian tumors, 5.00%, 10.00% in benign ovarian tumors ( χ2/ P=27.548/0.000, 31.335/0.000) . The mRNA and protein expression of IGF-1 and IGF-1R were also significantly higher than borderline ovarian tumors and benign ovarian tumors ( F/P=31.922/0.000, 26.865/0.000, 34.567/0.000, 27.667/0.000) . The positive expression rates of IGF-1 and IGF-1R in ovarian cancer with FIGOIII-IV stage, tissue differentiation G2-G3 stage, CA125>35 U/mL, Ki-67 positive expression were significantly higher than those in ovarian cancer with FIGOI-II stage, tissue differentiation G1 stage, CA125<35 U/mL, Ki-67 negative expression (IGF-1: χ2/ P=8.505/0.004, 4.980/0.026, 7.481/0.006, 10.907/0.001, IGF-1R: χ2/ P=9.785/0.002, 4.950/0.026, 7.211/0.007, 6.471/0.011) . The total survival time of ovarian cancer patients with positive IGF-1 and IGF-1R was shorter than those of patients with negative IGF-1 and IGF-1R. Conclusion:IGF-1 and IGF-1R are highly expressed in ovarian cancer and are associated with the deterioration of pathological features and surgical prognosis.
ABSTRACT
Objective To screen the preparation process of 3,4,3″-trihydroxy p-terphenyl nanosuspension. Methods The nanosuspension was prepared in combination with the nanoprecipitation and microfluidization method. Taken the particle size for indicator, we investigated the stirring speed and precipitation temperature in the nanoprecipitation process, the homogeneous stress and cycles in the microfluidic process through single factor experiment. In addition, by factorial design, the variety and dosage of stabilizers are investigated. Results The excellent preparation condition of the nanosuspension are as follows: 0 ℃ for the precipitation temperature, 900 rpm for the stirring speed, 1600 bar for the microfluidization pressure and 12 times for cycles. The ingredient ratio for drug: poloxamer 188: lecithin is 1: 0.8: 0.8. Conclusion Through optimizing the preparation technology, we have successfully prepared nanosuspension with lower size , which will lay a foundation for further study.